Original Article AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation

* Equal contributors. Received February 16, 2015; Accepted April 12, 2015; Epub April 15, 2015; Published May 1, 2015 Abstract: Metabolomic research has revealed that metabolites play an important role in prostate cancer devel- opment and progression. Previous studies have suggested that prostate cancer cell proliferation is induced by advanced glycation end products (AGEs) exposure, but the mechanism of this induction remains unknown. This study investigated the molecular mechanisms underlying the proliferative response of prostate cancer cell to the interaction of AGEs and the receptor for advanced glycation end products (RAGE). To investigate this mechanism, we used Western blotting to evaluate the responses of the retinoblastoma (Rb), p-Rb and PI3K/Akt pathway to AGEs stimulation. We also examined the effect of knocking down Rb and blocking the PI3K/Akt pathway on AGEs induced PC-3 cell proliferation. Our results indicated that AGE-RAGE interaction enhanced Rb phosphorylation and subse- quently decreased total Rb levels. Bioinformatics analysis further indicated a negative correlation between RAGE and RB1 expression in prostate cancer tissue. Furthermore, we observed that AGEs stimulation activated the PI3K/ Akt signaling pathway and that blocking PI3K/Akt signaling abrogated AGEs-induced cell proliferation. We report, for the first time, that AGE-RAGE interaction enhances prostate cancer cell proliferation by phosphorylation of Rb via the PI3K/Akt signaling pathway.

[1]  T. Zhao,et al.  AB124. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer , 2014, American journal of cancer research.

[2]  Pengfei Rong,et al.  Specific siRNA Targeting Receptor for Advanced Glycation End Products (RAGE) Decreases Proliferation in Human Breast Cancer Cell Lines , 2013, International journal of molecular sciences.

[3]  A. Pandey,et al.  A multicellular signal transduction network of AGE/RAGE signaling , 2012, Journal of Cell Communication and Signaling.

[4]  Chih-Hsin Tang,et al.  HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells. , 2012, Cancer letters.

[5]  D. Tang,et al.  The Role of Receptor for Advanced Glycation End Products (RAGE) in the Proliferation of Hepatocellular Carcinoma , 2012, International journal of molecular sciences.

[6]  K. Hemminki,et al.  The impact of type 2 diabetes mellitus on cancer‐specific survival , 2012, Cancer.

[7]  A. Kajdacsy-Balla,et al.  Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. , 2012, Biochemical and biophysical research communications.

[8]  C. Tseng.  Prostate cancer mortality in Taiwanese men: Increasing age-standardized trend in general population and increased risk in diabetic men , 2011, Annals of medicine.

[9]  K. Badani,et al.  Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. , 2010, Urology.

[10]  Yong Jiang,et al.  [Differential expressions of the receptor for advanced glycation end products in prostate cancer and normal prostate]. , 2010, Zhonghua nan ke xue = National journal of andrology.

[11]  W. Chazin,et al.  S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. , 2009, European journal of pharmacology.

[12]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[13]  P. Angel,et al.  The receptor RAGE: Bridging inflammation and cancer , 2009, Cell Communication and Signaling.

[14]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[15]  Todd M Morgan,et al.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. , 2009, Current cancer drug targets.

[16]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[17]  S. Yamagishi,et al.  AGE-RAGE system and carcinogenesis. , 2008, Current pharmaceutical design.

[18]  J. Kim,et al.  Advanced glycation end product (AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways. , 2008, International journal of oncology.

[19]  T. Arumugam,et al.  RAGE and RAGE ligands in cancer. , 2007, Current molecular medicine.

[20]  Pingfu Fu,et al.  Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion , 2007, International journal of cancer.

[21]  K. Knudsen,et al.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. , 2007, Cancer research.

[22]  D. Latini,et al.  History of Diabetes, Clinical Features of Prostate Cancer, and Prostate Cancer Recurrence-Data from CaPSURETM (United States) , 2005, Cancer Causes & Control.

[23]  Y. Kubota,et al.  Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development , 2005, The Prostate.

[24]  N. Greenberg,et al.  Conditional Deletion of Rb Causes Early Stage Prostate Cancer , 2004, Cancer Research.

[25]  D. Troyer,et al.  Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer , 2004, Cancer Research.

[26]  M. Osaki,et al.  Role of the Phosphatidylinositol 3′-Kinase–Akt Signal Pathway in the Proliferation of Human Pancreatic Ductal Carcinoma Cell Lines , 2004, Pancreas.

[27]  M. Horikoshi,et al.  Crystal Structure of the Homolog of the Oncoprotein Gankyrin, an Interactor of Rb and CDK4/6* , 2004, Journal of Biological Chemistry.

[28]  Xianglin Shi,et al.  Vanadate activated PI3K and Akt and promoted S phase entry , 2004, Molecular and Cellular Biochemistry.

[29]  Xianglin Shi,et al.  Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. , 2003, Biochemical and biophysical research communications.

[30]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[31]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[32]  D. Troyer,et al.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[34]  D. Tindall,et al.  Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. , 2001, Endocrinology.

[35]  W. Hung,et al.  Role of receptor for advanced glycation end‐product (RAGE) and the JAK/STAT‐signaling pathway in AGE‐induced collagen production in NRK‐49F cells , 2001, Journal of cellular biochemistry.

[36]  A. Barden,et al.  Advanced Glycation End Products: A Review , 2013 .

[37]  J. Harbour,et al.  Rb function in cell-cycle regulation and apoptosis , 2000, Nature Cell Biology.

[38]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[39]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[40]  R. Adam,et al.  The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. , 1999, Cancer research.

[41]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Trapman,et al.  Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. , 1998, Cancer research.

[43]  J. Melamed,et al.  Allelic loss on chromosome 13q in human prostate carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[45]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[46]  J. Neoptolemos,et al.  Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. , 1994, British Journal of Cancer.

[47]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.